Mission BioCapital

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

Cloverleaf Bio specializes in the development of an innovative RNA therapeutic platform focused on oncology. This platform enables the direct inhibition of cancer-promoting enzymes using a single therapeutic molecule, offering a novel approach to improve patient outcomes in cancer treatment.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Aperture Therapeutics is a biotechnology company dedicated to developing novel therapies for age-related neurodegenerative diseases. It employs a distinctive drug discovery platform that leverages the genetic diversity of patients to identify new disease pathways and drug targets. Currently in the pre-clinical stage, the company operates from a lab incubator, integrating insights from neuroscience and immunology to advance its research. Aperture Therapeutics' approach centers on the significance of genetic diversity in the discovery process, aiming to create more effective treatments for neurodegeneration and neuroimmunology conditions.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Ambagon Therapeutics is a biotechnology company focused on developing small-molecule therapeutics for cancer treatment. The company specializes in research aimed at stabilizing the interactions of oncogenic proteins, which are often difficult to modulate with traditional methods. By selectively enhancing the activity of tumor-suppressing proteins associated with transcription factors and oncoproteins, Ambagon aims to provide new therapeutic options for addressing significant unmet clinical needs in oncology. Founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin, the company is dedicated to advancing innovative solutions in cancer care.

Tune Therapeutics develops cell and gene therapies guided by epigenetic programming to treat devastating diseases. The company is building an epigenetic programming platform that enables new pathways for disease treatment by tapping into the epigenome to program biology without altering the DNA sequence. This approach aims to deliver paradigm-changing therapies by modulating gene expression through epigenetic mechanisms rather than editing the genome, expanding options for diseases where conventional treatments have limited efficacy. By integrating epigenetics and cell biology, the company seeks durable, precise interventions that can reprogram cellular states to restore function while minimizing genetic change. The emphasis is on research and development to advance candidates toward clinical use to address severe and unmet medical needs.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.

Totient Inc. is an AI-driven biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in using advanced machine learning and immunoinformatics to analyze complex datasets in the field of drug discovery and development. It focuses on identifying novel tissue-specific antigens and reconstructing high-affinity antibody therapeutics from tissues impacted by cancer, autoimmune diseases, and infections. By leveraging its platform's unique capabilities, Totient aims to quickly and accurately identify potent antibody candidates suitable for a variety of therapeutic applications, including cell therapies and bispecific antibodies. This innovative approach positions the company to address significant medical challenges in multiple areas of healthcare.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Shape Therapeutics, Inc. is a biotechnology company focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic disorders. Founded in 2018 and headquartered in Seattle, Washington, the company utilizes its proprietary RNAfix technology to edit RNA using the body’s natural cellular machinery. This approach minimizes risks associated with immunogenicity, cellular toxicity, and unintended DNA editing. Shape Therapeutics is dedicated to advancing its innovative platforms for payload, delivery, and manufacturing to enable the development of effective treatments, aiming to address critical health challenges and improve patient outcomes.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Telo Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics aimed at reversing cancer cell immortality. The company employs a precision medicine approach to target telomerase, an enzyme that cancer cells utilize during the immortalization process. By inhibiting this enzyme, Telo Therapeutics seeks to leave healthy cells unscathed while improving treatment outcomes for patients who have exhausted other options. Through its unique platform, the company aspires to enhance survival and well-being in cancer patients, ultimately contributing to more effective treatment strategies and potential cures for various forms of cancer.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Sentieon, Inc. is a bioinformatics company based in Mountain View, California, founded in 2014. It specializes in developing and commercializing cloud-based solutions for the life sciences and clinical markets. Sentieon offers a range of bioinformatics tools designed for processing genomics data with a focus on accuracy, efficiency, and quick turnaround times. Its notable products include Sentieon DNAseq, which aids in germline DNA analysis, and Sentieon TNseq, designed for detecting tumor-normal somatic variants. These software-only tools boast scalability and upgradeability, leveraging optimized algorithms to improve computing performance. Sentieon aims to enhance the capabilities of scientists and clinicians by providing precision tools that facilitate comprehensive tumor characterization and other critical bioinformatics processes.